Last reviewed · How we verify
Shigella conjugate vaccines
Shigella conjugate vaccines stimulate the immune system to produce antibodies against Shigella bacterial antigens by conjugating polysaccharide antigens to protein carriers.
Shigella conjugate vaccines stimulate the immune system to produce antibodies against Shigella bacterial antigens by conjugating polysaccharide antigens to protein carriers. Used for Prevention of Shigella infection and shigellosis (bacterial dysentery).
At a glance
| Generic name | Shigella conjugate vaccines |
|---|---|
| Also known as | S. sonnei O-SP-rEPA conjugate., S. flexneri 2a O-SP-rEPA conjugate. |
| Sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Drug class | Bacterial conjugate vaccine |
| Target | Shigella lipopolysaccharide (LPS) and surface antigens |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
These vaccines work by presenting Shigella lipopolysaccharide (LPS) or other surface antigens conjugated to carrier proteins, which enhances T-cell dependent immune responses and generates both humoral and cellular immunity. The conjugate approach improves immunogenicity compared to unconjugated polysaccharide vaccines, particularly in younger populations. This elicits protective antibodies that prevent Shigella infection and associated dysentery.
Approved indications
- Prevention of Shigella infection and shigellosis (bacterial dysentery)
Common side effects
- Injection site pain or erythema
- Fever
- Myalgia
- Fatigue
Key clinical trials
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children (PHASE2)
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (PHASE1)
- First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults (PHASE1)
- Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine (PHASE2)
- A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a (PHASE2)
- Shigella Sonnel O-SPC/rBRU Conjugate Vaccine (PHASE1)
- SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: